Rate My Professor Stephen Ting

Stephen Ting is an Adjunct Clinical Associate Professor and Haematology clinician-scientist based at Alfred Health-Monash University and the Eastern Health Clinical School, Faculty of Medicine. He completed his medical training in clinical and laboratory haematology at Monash University and affiliated hospitals in 1998. He received postgraduate scholarships from the Haematology Society of Australia and New Zealand to study polycythaemia at Hôpital Cochin, Paris in 1999, and from the Cancer Council of Victoria for PhD studies (2000-2005) with Professor Stephen Jane at the Bone Marrow Research Laboratories. Between 2006 and 2009, he held NHMRC CJ Martin, Canadian Post-Doctoral, and RACP Bushell Travelling Fellowships. As a practising haematologist, he serves as consultant haematologist at Alfred Hospital, Melbourne, with inpatient and outpatient duties, and VMO consultant haematologist at Cabrini Hospital, Malvern. He returned to Peter MacCallum Cancer Centre in 2010 as senior Research Fellow and was appointed group leader in the Division of Blood Cancers, Australian Centre for Blood Diseases in mid-2011. He is Director of Clinical Haematology at Eastern Health and Principal Investigator.

Ting's research investigates molecular mechanisms of haematopoietic and leukaemia stem cell self-renewal, asymmetric cell division in haematopoietic stem cells, the mitotic spindle during stem cell division, and genes including Kif3 in acute T-cell leukaemia and Ap2a2 as an asymmetrically segregating protein linking to self-renewal. He employs functional screens for endocytosis and cytoskeleton genes enhancing stem cell activity and mouse models to assess leukaemia outcomes. His research has attracted $1.5 million from NHMRC, Cancer Council of Victoria, Leukaemia Foundation, and RACP, with publications in Science, Nature Medicine, Cell, Cell Stem Cell, Developmental Cell, and Blood. Recent works include 'Final analysis of the phase 1b Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT)' (2025), 'Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: Protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials' (2024), 'Increased STAT expression in Reed–Sternberg cells as a potential positive prognostication biomarker in Hodgkin lymphoma' (2023), 'Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG' (2023), and 'The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry' (2023). Awards include Victorian Premier’s Award in Medical Research (2005), International Society of Stem Cell Research Travel Awards (2010, 2012), and Cleveland Young Investigator Award (2003). He is a member of NHMRC, Royal College of Pathologists of Australasia, Royal Australasian College of Physicians, and Alfred Hospital, and speaks at annual Leukemia Foundation patient symposia since 2013.